Announcements Trials
Browse Landscape

Phase

Phase 3 1Phase 2/3 1

Status

Recruiting 2

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

CNS 1

Conditions

Prostatic Neoplasms 2Neoplasms 2Fatigue 2Sleep Wake Disorders 1Recurrence 1Neoplasm Metastasis 1Hematologic Neoplasms 1Depression 1Brain Neoplasms 1Anxiety Disorders 1

Interventions

pembrolizumab 90Blood Specimen Collection 45Cyclophosphamide 37Bevacizumab 37Nivolumab 36Standard of Care 32Carboplatin 31Surveys and Questionnaires 29Paclitaxel 28atezolizumab 25Exercise 25Pemetrexed 24Gemcitabine 24Fluorouracil 23Cisplatin 23Leucovorin 21Radiotherapy 20Dexamethasone 20Oxaliplatin 19Docetaxel 19Rituximab 16Irinotecan 16Cetuximab 16dostarlimab 15Ipilimumab 15Drug Therapy 15Doxorubicin 15Biopsy 15130-nm albumin-bound paclitaxel 15Prednisone 14

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Neoplasms × Methylphenidate × 1 year × Clear all
NCT06905587 2026-04-23

EMBRAIN

Odense University Hospital

Phase 3 Recruiting
50 enrolled
CNS

Brain Neoplasms, Neoplasms

NCT05474846 2025-11-06

Combination Therapy for Treatment of Sleep Disturbance in Patients With Advanced Cancer

M.D. Anderson Cancer Center

Phase 2/3 Recruiting
188 enrolled

Anxiety Disorders, Depression, Fatigue, Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon âš¡